Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis.
about
Regulation of atherogenesis by chemokines and chemokine receptorsInflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applicationsSerum CXCL16 as a novel marker of renal injury in type 2 diabetes mellitusZmynd15 encodes a histone deacetylase-dependent transcriptional repressor essential for spermiogenesis and male fertilityPeripheral arterial occlusive disease: global gene expression analyses suggest a major role for immune and inflammatory responses.Comprehensive assessment of chemokine expression profiles by flow cytometryPlatelets and their chemokines in atherosclerosis-clinical applications.Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular diseaseFunction modification of SR-PSOX by point mutations of basic amino acids.An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cellsLymphocyte migration into atherosclerotic plaque.Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets.Genetic basis of atherosclerosis: insights from mice and humansEnhanced penetration of exogenous EPCs into brains of APP/PS1 transgenic mice.The perioperative time course and clinical significance of the chemokine CXCL16 in patients undergoing cardiac surgeryChemokines: inflammatory mediators of atherosclerosis.CXCR6 regulates the recruitment of pro-inflammatory IL-17A-producing T cells into atherosclerotic aortasImmune and inflammatory mechanisms of atherosclerosis (*)Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion.Semi-Automated Curation Allows Causal Network Model Building for the Quantification of Age-Dependent Plaque Progression in ApoE-/- Mouse.Activation of the CXCL16/CXCR6 Pathway by Inflammation Contributes to Atherosclerosis in Patients with End-stage Renal DiseaseInternational Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis.Targeting Innate Immunity for CV Benefit.Elevation of serum CXCL16 level correlates well with atherosclerotic ischemic stroke.Chemokines in the vascular inflammatory response of atherosclerosis.The role of chemokines in recruitment of immune cells to the artery wall and adipose tissueChemokines: established and novel targets in atherosclerosis.Molecular biology of atherosclerosis.Regulation of atherosclerotic plaque inflammation.Overexpression of CXCL16 in lesional psoriatic skin.CXC chemokine ligand 16 is increased in gestational diabetes mellitus and preeclampsia and associated with lipoproteins in gestational diabetes mellitus at 5 years follow-up.Homocysteine up-regulates vascular transmembrane chemokine CXCL16 and induces CXCR6+ lymphocyte recruitment in vitro and in vivo.Shear Stress Counteracts Endothelial CX3CL1 Induction and Monocytic Cell Adhesion.Prone myocardial perfusion imaging following multislice CT coronary artery scanning as an aid to evaluation in women.Correlations of chemokine CXCL16 and TNF-α with coronary atherosclerotic heart disease.Natural killer cell memory.OxLDL-mediated survival of macrophages does not require LDL internalization or signalling by major pattern recognition receptors.
P2860
Q27003124-E21623B4-B41C-461F-A800-950E7C304365Q28275259-F1955CD6-8926-4967-9088-69EC1954BC5CQ28539322-07EAEF1B-11C8-4E9A-A2D1-AF26CE063F5DQ28592842-3AF3F3CE-B639-41CA-9F56-6D4B9F7ED8B1Q33357022-1DD41723-16EA-4E94-9A9E-CDA5A7986BA4Q33685627-4067E131-BAEA-4254-8218-13B85F5D87D6Q34019069-93216732-0D9C-40BE-BA6B-0770B1CEC8B6Q34218552-8D4EE5FB-6AAF-4AFC-AC5D-B1D35B2D4BB6Q35009160-1CD769E2-A2AB-4059-8869-45B8AA646D67Q35534748-3BD0D1E7-6A86-4C4F-9504-0D40F7CF302EQ35600904-21183E34-3064-417D-BCE9-B28642126C12Q35640438-D6D88E95-BF05-49F2-ADF9-0DE67F377D48Q35975437-67B741A8-D2A2-4599-8D2A-9FE5F5E7F36FQ36019557-1D5F5D2D-8333-475C-BE74-AD834916EB75Q36476906-62209053-5C88-4B37-A921-7C525B4BE1F9Q36687945-C14148CB-5454-4661-8E17-FD2E7DD7A6A9Q36954815-22C324AE-7655-49C2-B11B-A7A9089A9FE3Q37325024-630FAC0F-C4A7-4D6B-8106-ED314BED37C6Q37339764-C03D6763-C0D8-41C2-8E7B-598020525E02Q37401478-C48B51F7-08F1-4792-AB9D-4566B17D92ECQ37428143-8B69248C-2681-4E2C-A7CA-2C71B0FDD0F4Q37432097-3968B118-E19C-42ED-8D73-EFF1713FF1E7Q37435783-FFFD7572-7CE7-4CEA-9ED2-DDE03546EEF3Q37476718-76D178E5-5856-4A60-A029-A8E1F9C31253Q37636842-BE7F284E-9E50-41D2-B8A6-B1393333536EQ37652971-8E73B0D0-4858-40CB-B07E-D1494F1B4CDDQ37660659-96AD0FF6-0F8C-4511-9CAA-859F8126BA64Q37950973-7C14F9D5-404C-40AB-9628-FF3513F63B93Q38125279-D8B431A4-2A80-4238-99E4-10A19C31A062Q38396097-AF35E21A-482A-49BB-9F6A-090846F15666Q39533961-A129627B-0E6A-4E3C-A3E1-FD56E183DBC2Q40073242-8FA2CC26-7632-432E-9E7A-1485D58A1AB1Q41933923-50DB5620-2918-4BD1-8A1F-E2F50B1E3909Q42201674-2DFD62BF-66C1-47BA-A6B4-E67C93A3C0E6Q46094499-F4274596-6055-45F4-9727-BE0FA61DBF54Q49335652-B0509614-BAEC-47C5-8D22-2F8A7526EE32Q51000689-F6DAC943-F0EB-4FAF-8F5E-E959DA595521Q54569622-8CE0A76E-0314-49E8-A635-3FBE6A6A0F4F
P2860
Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Targeted disruption of the sca ...... 6 accelerates atherosclerosis.
@ast
Targeted disruption of the sca ...... 6 accelerates atherosclerosis.
@en
Targeted disruption of the sca ...... 6 accelerates atherosclerosis.
@nl
type
label
Targeted disruption of the sca ...... 6 accelerates atherosclerosis.
@ast
Targeted disruption of the sca ...... 6 accelerates atherosclerosis.
@en
Targeted disruption of the sca ...... 6 accelerates atherosclerosis.
@nl
prefLabel
Targeted disruption of the sca ...... 6 accelerates atherosclerosis.
@ast
Targeted disruption of the sca ...... 6 accelerates atherosclerosis.
@en
Targeted disruption of the sca ...... 6 accelerates atherosclerosis.
@nl
P1433
P1476
Targeted disruption of the sca ...... 6 accelerates atherosclerosis.
@en
P2093
Ara M Aslanian
Israel F Charo
P304
P356
10.1161/CIRCULATIONAHA.105.540583
P407
P577
2006-07-31T00:00:00Z